BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 38685813)

  • 1. Preclinical testing of CT1113, a novel USP28 inhibitor, for the treatment of T-cell acute lymphoblastic leukaemia.
    Xu J; Peng J; Sun S; Wang D; Yuan W; Yang X; Shi T; Wang R; Liu H; Zhang P; Zhu HH
    Br J Haematol; 2024 Jun; 204(6):2301-2318. PubMed ID: 38685813
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Flavone inhibited proliferation of T-ALL by promoting c-Cbl-induced ubiquitinylation and degradation of Notch1.
    Zhu W; Zhu Y; Xu H; Wang T; Wang J; Meng M; Liu Y; Yan H; Yang Q; Liu P
    Biochem Biophys Res Commun; 2020 Feb; 522(3):684-689. PubMed ID: 31785807
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular pathogenesis and targeted therapies for NOTCH1-induced T-cell acute lymphoblastic leukemia.
    Paganin M; Ferrando A
    Blood Rev; 2011 Mar; 25(2):83-90. PubMed ID: 20965628
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Notch1 regulates chemotaxis and proliferation by controlling the CC-chemokine receptors 5 and 9 in T cell acute lymphoblastic leukaemia.
    Mirandola L; Chiriva-Internati M; Montagna D; Locatelli F; Zecca M; Ranzani M; Basile A; Locati M; Cobos E; Kast WM; Asselta R; Paraboschi EM; Comi P; Chiaramonte R
    J Pathol; 2012 Apr; 226(5):713-22. PubMed ID: 21984373
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stabilization of Notch1 by the Hsp90 Chaperone Is Crucial for T-Cell Leukemogenesis.
    Wang Z; Hu Y; Xiao D; Wang J; Liu C; Xu Y; Shi X; Jiang P; Huang L; Li P; Liu H; Qing G
    Clin Cancer Res; 2017 Jul; 23(14):3834-3846. PubMed ID: 28143869
    [No Abstract]   [Full Text] [Related]  

  • 6. The Genetics and Mechanisms of T-Cell Acute Lymphoblastic Leukemia.
    Gianni F; Belver L; Ferrando A
    Cold Spring Harb Perspect Med; 2020 Mar; 10(3):. PubMed ID: 31570389
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chidamide inhibits the NOTCH1-MYC signaling axis in T-cell acute lymphoblastic leukemia.
    Xi M; Guo S; Bayin C; Peng L; Chuffart F; Bourova-Flin E; Rousseaux S; Khochbin S; Mi JQ; Wang J
    Front Med; 2022 Jun; 16(3):442-458. PubMed ID: 34669156
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The NOTCH1-MYC highway toward T-cell acute lymphoblastic leukemia.
    Sanchez-Martin M; Ferrando A
    Blood; 2017 Mar; 129(9):1124-1133. PubMed ID: 28115368
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Notch1 is required for hypoxia-induced proliferation, invasion and chemoresistance of T-cell acute lymphoblastic leukemia cells.
    Zou J; Li P; Lu F; Liu N; Dai J; Ye J; Qu X; Sun X; Ma D; Park J; Ji C
    J Hematol Oncol; 2013 Jan; 6():3. PubMed ID: 23289374
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blockade of Oncogenic NOTCH1 with the SERCA Inhibitor CAD204520 in T Cell Acute Lymphoblastic Leukemia.
    Marchesini M; Gherli A; Montanaro A; Patrizi L; Sorrentino C; Pagliaro L; Rompietti C; Kitara S; Heit S; Olesen CE; Møller JV; Savi M; Bocchi L; Vilella R; Rizzi F; Baglione M; Rastelli G; Loiacono C; La Starza R; Mecucci C; Stegmaier K; Aversa F; Stilli D; Lund Winther AM; Sportoletti P; Bublitz M; Dalby-Brown W; Roti G
    Cell Chem Biol; 2020 Jun; 27(6):678-697.e13. PubMed ID: 32386594
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic antibody targeting of Notch1 in T-acute lymphoblastic leukemia xenografts.
    Agnusdei V; Minuzzo S; Frasson C; Grassi A; Axelrod F; Satyal S; Gurney A; Hoey T; Seganfreddo E; Basso G; Valtorta S; Moresco RM; Amadori A; Indraccolo S
    Leukemia; 2014 Feb; 28(2):278-88. PubMed ID: 23774673
    [TBL] [Abstract][Full Text] [Related]  

  • 12. USP28: Oncogene or Tumor Suppressor? A Unifying Paradigm for Squamous Cell Carcinoma.
    Prieto-Garcia C; Tomašković I; Shah VJ; Dikic I; Diefenbacher M
    Cells; 2021 Oct; 10(10):. PubMed ID: 34685632
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NOTCH1 activation clinically antagonizes the unfavorable effect of PTEN inactivation in BFM-treated children with precursor T-cell acute lymphoblastic leukemia.
    Bandapalli OR; Zimmermann M; Kox C; Stanulla M; Schrappe M; Ludwig WD; Koehler R; Muckenthaler MU; Kulozik AE
    Haematologica; 2013 Jun; 98(6):928-36. PubMed ID: 23349303
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The relevance of PTEN-AKT in relation to NOTCH1-directed treatment strategies in T-cell acute lymphoblastic leukemia.
    Mendes RD; Canté-Barrett K; Pieters R; Meijerink JP
    Haematologica; 2016 Sep; 101(9):1010-7. PubMed ID: 27582570
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Loss of oncogenic Notch1 with resistance to a PI3K inhibitor in T-cell leukaemia.
    Dail M; Wong J; Lawrence J; O'Connor D; Nakitandwe J; Chen SC; Xu J; Lee LB; Akagi K; Li Q; Aster JC; Pear WS; Downing JR; Sampath D; Shannon K
    Nature; 2014 Sep; 513(7519):512-6. PubMed ID: 25043004
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The deubiquitinase USP28 controls intestinal homeostasis and promotes colorectal cancer.
    Diefenbacher ME; Popov N; Blake SM; Schülein-Völk C; Nye E; Spencer-Dene B; Jaenicke LA; Eilers M; Behrens A
    J Clin Invest; 2014 Aug; 124(8):3407-18. PubMed ID: 24960159
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genomic characterization of pediatric T-cell acute lymphoblastic leukemia reveals novel recurrent driver mutations.
    Spinella JF; Cassart P; Richer C; Saillour V; Ouimet M; Langlois S; St-Onge P; Sontag T; Healy J; Minden MD; Sinnett D
    Oncotarget; 2016 Oct; 7(40):65485-65503. PubMed ID: 27602765
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elevated TRIB2 with NOTCH1 activation in paediatric/adult T-ALL.
    Hannon MM; Lohan F; Erbilgin Y; Sayitoglu M; O'Hagan K; Mills K; Ozbek U; Keeshan K
    Br J Haematol; 2012 Sep; 158(5):626-34. PubMed ID: 22775572
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IL-7R is essential for leukemia-initiating cell activity of T-cell acute lymphoblastic leukemia.
    González-García S; Mosquera M; Fuentes P; Palumbo T; Escudero A; Pérez-Martínez A; Ramírez M; Corcoran AE; Toribio ML
    Blood; 2019 Dec; 134(24):2171-2182. PubMed ID: 31530562
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolic reprogramming induces resistance to anti-NOTCH1 therapies in T cell acute lymphoblastic leukemia.
    Herranz D; Ambesi-Impiombato A; Sudderth J; Sánchez-Martín M; Belver L; Tosello V; Xu L; Wendorff AA; Castillo M; Haydu JE; Márquez J; Matés JM; Kung AL; Rayport S; Cordon-Cardo C; DeBerardinis RJ; Ferrando AA
    Nat Med; 2015 Oct; 21(10):1182-9. PubMed ID: 26390244
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.